MANCHESTER, England--(BUSINESS WIRE)--Oxyrane, a privately-owned biotechnology company with a head office in Manchester, (England) and research operations in Gent, (Belgium), announced today that it has opened a new operation in Burlington, Massachusetts (USA). The new operation is an important step in the company’s evolution as it progresses clinical development of its innovative enzyme replacement therapy-based solution that has the potential to address numerous unmet clinical needs across a range of lysosomal storage disorders (LSDs).
